XIENCE V is the DES designed for deliverability, efficacy, and safety. Every element of the stent system has been evaluated to bring you a true next-generation DES. That means a low drug load, thinnest struts, and excellent polymer integrity for rapid healing. 1

    Design goal: lowest drug load, thinnest struts, and excellent polymer integrity for rapid healing.1



Thin struts for less injury 2

  • 0.0032” strut thickness 3
  • Clinically proven MULTI-LINK VISION CoCr stent
  • World's #1 metallic stent 4


Superb deliverability

  • Low balloon outside the stent to reduce injury 5, 6


Controlled release, low dose of everolimus

  • Cytostatic drug


Biocompatible fluorinated copolymer

  • Thin, durable

Access tools and resources>

1Joner, M., G. Nakazawa, et al. (2008). J Am Coll Cardiol 52(5):333-42.

2Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-II) trial. JACC. 2003; 41(8).

3Manufacturer-reported strut thickness. Data on file at Abbott Vascular.

4U.S. Market Overview report. December 2007. Published by PGM. Data on file at Abbott Vascular.

5Tests performed by and data on file at Abbott Vascular.

6Carter, A.J. Experimental evaluation of a short transitional edge protection balloon for intracoronary stent deployment. CCI. 2000;51:112-119.


* In SPIRIT II, XIENCE V demonstrated superiority versus TAXUS stents with a statistically significant 69% reduction in the primary endpoint of in-stent late loss at 6 months (0.11mm vs 0.36mm; PNI and PSUP<0.0001). Both TAXUS Express2 (73% of lesions) and TAXUS Liberte (27% of lesions) were used as controls in SPIRIT II. Source: P. Serruys et al. EuroIntervention 2006; 2:286-294 & data on file at Abbott Vascular. In SPIRIT III, XIENCE V demonstrated superiority versus TAXUS Express2 with a statistically significant 50% reduction in the primary endpoint of in-segment late loss at 8 months (0.14mm vs 0.28mm; PNI <0.0001, PSUP=0.004). Source: G. Stone et al. JAMA 2008; 299(16):1903-1913.

* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.